脑转移患者的发作风险因素和治疗方法
Eugene J Vaios1, Spencer Maingi1, Kristen Batich2,3
1Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA.
Neuro-oncology practice
|June 9, 2025
概括
在脑转移的患者中,发作很常见,受各种因素的影响. 目前的指导方针经常建议不使用预防性抗发作药物,强调需要更好的风险评估和管理策略.
科学领域:
- 神经瘤学神经瘤学
- 神经学 神经学
- 临床医学 临床医学
背景情况:
- 发作是脑转移患者的重要并发症,影响了发病率和结果.
- 风险因素包括患者特征,代谢问题,瘤负担和治疗类型.
研究的目的:
- 对大脑转移的当前发作管理标准进行审查.
- 评估多模式治疗对发作风险的影响.
- 识别知识缺口和未来的研究方向.
主要方法:
- 综合文献综述. 这是一个全面的文献综述.
- 对脑转移中发作风险因素的分析.
- 对预防性抗发作药物指导方针和临床实践的评估.
主要成果:
- 在大脑转移中,发作风险是多因素的.
- 预防性抗发作药物的使用是有争议的,指南经常建议不要使用它.
- 临床实践有所不同,这表明需要更新理解.
结论:
- 目前对脑转移中发作风险的理解需要更新,特别是多模式治疗.
- 需要改进风险分层和管理策略.
- 进一步的研究对于优化患者护理和结果至关重要.
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
266
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
266
Arteries of the Lower Limbs
181
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
181
Seizures: Classification
307
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
307
Antiepileptic Drugs: Glutamate Antagonists
292
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
292
Antiepileptic Drugs: Potassium Channel Activators
149
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
149
Antiepileptic Drugs: GABAergic Pathway Potentiators
341
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
341


